Malta - English - Medicines Authority

biofarm sp. zo.o walbrzyska str 13, 60-198, poznan, poland - rosuvastatin - film-coated tablet - rosuvastatin 5 mg - lipid modifying agents

Malta - English - Medicines Authority

biofarm sp. zo.o walbrzyska str 13, 60-198, poznan, poland - rosuvastatin - film-coated tablet - rosuvastatin 10 mg - lipid modifying agents

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - rosuvastatin - film coated tablet - 5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

clear pharmacy - rosuvastatin - film coated tablet - 10 milligram - hmg coa reductase inhibitors

New Zealand - English - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - rosuvastatin calcium 10.4mg equivalent to rosuvastatin 10mg;   - film coated tablet - 10 mg - active: rosuvastatin calcium 10.4mg equivalent to rosuvastatin 10mg   excipient: calcium phosphate crospovidone hypromellose iron oxide red lactose monohydrate   magnesium stearate microcrystalline cellulose purified water titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation

New Zealand - English - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - rosuvastatin calcium 41.6mg equivalent to rosuvastatin 40mg;   - film coated tablet - 40 mg - active: rosuvastatin calcium 41.6mg equivalent to rosuvastatin 40mg   excipient: calcium phosphate crospovidone hypromellose iron oxide red lactose monohydrate   magnesium stearate microcrystalline cellulose purified water titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation

New Zealand - English - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - rosuvastatin calcium 5.2mg equivalent to rosuvastatin 5mg;   - film coated tablet - 5 mg - active: rosuvastatin calcium 5.2mg equivalent to rosuvastatin 5mg   excipient: calcium phosphate crospovidone hypromellose iron oxide yellow lactose monohydrate   magnesium stearate microcrystalline cellulose titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - rosuvastatin calcium 20.80 mg eqv rosuvastatin - tablet, film coated - 20 mg - rosuvastatin calcium 20.80 mg eqv rosuvastatin 20 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration